Does Kathleen Rubins have any related-party transactions with FibroBiologics (FBLG)?

FibroBiologics stated that Dr. Rubins is not party to any transaction requiring disclosure under Item 404(a) of Regulation S-K. The company also entered into its standard indemnification agreement with her, providing protection against certain liabilities associated with serving as a director.

Ex-astronaut Kate Rubins joins FibroBiologics (NASDAQ: FBLG) board

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

FibroBiologics, Inc. reported a board change, with Matt Link resigning as a director effective July 2, 2026, and the board appointing Kathleen “Kate” Rubins, Ph.D., as a Class III director effective July 8, 2026, with a term running to the 2029 annual stockholders’ meeting.

Dr. Rubins, a retired NASA astronaut, microbiologist and genomics scientist, becomes a member of the Audit, Compensation, and Governance and Nominating Committees and will receive compensation under the company’s Non-Employee Director Compensation Policy. A press release describing her appointment, including her 300 days in space and leadership at the Trivedi Institute for Space and Global Biomedicine, was furnished as an exhibit.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Director resignation effective date: July 2, 2026 New director appointment date: July 8, 2026 Director term end: 2029 annual meeting +3 more

6 metrics

Director resignation effective date July 2, 2026 Matt Link resignation from Board of Directors

New director appointment date July 8, 2026 Kathleen Rubins appointed Class III director

Director term end 2029 annual meeting End of Class III director term for Rubins

Time spent in space 300 days Rubins’ cumulative time on International Space Station

Patents issued and pending 270+ patents FibroBiologics’ intellectual property portfolio

NASA service duration 16 years Rubins’ tenure at NASA before retiring in 2025

Key Terms

Emerging growth company, Regulation FD Disclosure, Non-Employee Director Compensation Policy, indemnification agreement, +2 more

6 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure. A copy of the Company’s press release"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

Non-Employee Director Compensation Policy financial

"compensation consistent with that of the Company’s other non-employee directors under the Company’s Non-Employee Director Compensation Policy"

indemnification agreement regulatory

"entered into its standard form of indemnification agreement with Dr. Rubins"

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

clinical-stage biotechnology company financial

"FibroBiologics, Inc. (Nasdaq: FBLG) “FibroBiologics”), a clinical-stage biotechnology company"

fibroblast cell therapy financial

"advances fibroblast cell therapy from the lab toward patients who need new treatment options"

A therapy that uses fibroblast cells—natural cells that build and repair connective tissue like skin and scars—to promote healing or restore damaged tissue. For investors, it matters because these treatments can offer lasting, biologically based solutions with potential for premium pricing and market demand, but they also carry high clinical-development, manufacturing and regulatory risks similar to other cell therapies, so success depends on proven safety, efficacy and scalable production.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/09/2026 - 09:32 AM Accepted by SEC EDGAR 07/09/2026 - 09:31 AM

FAQ

What board changes did FibroBiologics (FBLG) disclose in this 8-K?

FibroBiologics disclosed that Matt Link resigned from its Board of Directors on July 2, 2026. The company then appointed Kathleen “Kate” Rubins, Ph.D., as a Class III director effective July 8, 2026, with a term extending to the 2029 annual stockholders’ meeting.

Who is Kathleen "Kate" Rubins, the new FibroBiologics (FBLG) director?

Kathleen “Kate” Rubins is a microbiologist, genomics scientist, and retired NASA astronaut. She has logged 300 days in space, became the first person to sequence DNA in space, and is Founding Director of the Trivedi Institute for Space and Global Biomedicine at the University of Pittsburgh.

What board committees will Dr. Rubins serve on at FibroBiologics (FBLG)?

Dr. Rubins will serve on FibroBiologics’ Audit Committee, Compensation Committee, and Governance and Nominating Committee. These assignments give her a role in financial oversight, executive pay decisions, and broader corporate governance, aligning her scientific background with key board responsibilities.

How will FibroBiologics (FBLG) compensate Dr. Rubins as a director?

Dr. Rubins will receive compensation consistent with FibroBiologics’ Non-Employee Director Compensation Policy. This means her pay and benefits match those of other non-employee directors, with terms governed by an existing policy that may be amended periodically by the company.

What does FibroBiologics (FBLG) focus on as a business?

FibroBiologics is a clinical-stage biotechnology company developing treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds more than 270 issued and pending patents across areas including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, longevity, and cancer.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): July 02, 2026

    

FibroBiologics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-41934	86-3329066
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9350 Kirby Drive, Suite 300
Houston, Texas		77054
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 281 671-5150

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.00001 par value	FBLG	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 2, 2026, Matt Link notified FibroBiologics, Inc. (the “Company”) that he was resigning from the Board of Directors (the “Board”), effective as of July 2, 2026.

On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D. as a Class III director of the Board, effective July 8, 2026, to serve until the expiration of her term at the 2029 annual meeting of stockholders. Dr. Rubins was also appointed to serve on the Board’s Audit Committee, Compensation Committee and Governance and Nominating Committee.

Dr. Rubins is the Founding Director, Trivedi Institute for Space and Global Biomedicine, and a Professor of Computational and Systems Biology at the University of Pittsburgh School of Medicine. She is also a US Army Reserve Innovation Officer, Major/O-4 in the 75th US Army Innovation Command. From August 2009 through July 2025, Dr. Rubins served as an Astronaut in the National Aeronautics and Space Administration (NASA). Dr. Rubins received her Ph.D. in Cancer Biology from Stanford University and a Bachelor of Science in Molecular Biology from the University of California, San Diego (UCSD).

In connection with her appointment, Dr. Rubins will be entitled to receive compensation consistent with that of the Company’s other non-employee directors under the Company’s Non-Employee Director Compensation Policy, as such policy may be amended from time to time.

Dr. Rubins is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Dr. Rubins and any other persons pursuant to which she was selected as a director.

The Company also entered into its standard form of indemnification agreement with Dr. Rubins, which will require the Company to indemnify Dr. Rubins against certain liabilities that may arise as a result of her status or service as a director of the Company. The description of the Company’s standard form of indemnification agreement is qualified in its entirety by reference to the full text of the form of indemnification agreement, a copy of which is filed as Exhibit 10.19 to the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2026.

Item 7.01 Regulation FD Disclosure.

A copy of the Company’s press release announcing the appointment of Dr. Rubins to the Board has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.

The information in this report furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

Item 9.01 Financial Statements and Exhibits.


Exhibit 99.1		Press Release
Exhibit 104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			FibroBiologics, Inc.

Date:	July 9, 2026	By:	/s/ Pete O'Heeron
			Name: Pete O'Heeron Title: Chief Executive Officer

Exhibit 99.1

FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors

Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trivedi Institute for Space and Global Biomedicine Joins Board

HOUSTON, July 9, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Kathleen "Kate" Rubins, Ph.D. to its Board of Directors. As a retired NASA astronaut, microbiologist, and genomics scientist, Dr. Rubins has conducted pioneering medical research on the immune response to infection at high-profile academic institutions and pioneered molecular, cellular, and genomic techniques for human health on board the International Space Station (ISS).

Pete O'Heeron, Chief Executive Officer and Chairman of FibroBiologics, said, “Kate has been an invaluable member of our Scientific Advisory Board since 2022, and her firsthand understanding of how the human body adapts and heals in extreme environments makes her a natural fit for this expanded role. As we continue to advance our fibroblast-based pipeline through clinical development, her perspective will help guide both our scientific strategy and our long-term vision for FibroBiologics.”

“FibroBiologics is pursuing a fundamentally different approach to treating chronic disease, and I have seen the depth of the science behind it,” said Dr. Rubins. “I am honored to take on this expanded role and to help guide the company as it advances fibroblast cell therapy from the lab toward patients who need new treatment options.”

Dr. Rubins is the Founding Director of the Trivedi Institute for Space and Global Biomedicine at the University of Pittsburgh School of Medicine. Selected by NASA in 2009 as part of Astronaut Group 20, she completed two spaceflights to the ISS, serving as a flight engineer on Expedition 48/49 and Expedition 63/64 and has logged a total of 300 days in space. During her first mission, she became the first person to sequence DNA in space, advancing research into how astronauts can diagnose illness and identify microbes aboard the space station. Dr. Rubins retired from NASA in 2025 after 16 years with the agency, and was elected to the National Academy of Medicine in 2025.

Prior to joining NASA, Dr. Rubins was a Fellow and Principal Investigator at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology, where she led a lab studying how the human immune system responds to serious infectious diseases and developing potential new treatments. She holds a B.S. in Molecular Biology from the University of California, San Diego, and a Ph.D. in Cancer Biology from Stanford University Medical School.

Exhibit 99.1

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases

EX-99.1 EX-99.1 16.8 KB